Time trends in statin utilisation and coronary mortality in Western European countries

Federico Vancheri,1,2 Lars Backlund,2 Lars-Erik Strender,2 Brian Godman,3,4 Björn Wettermark5,6

ABSTRACT

Objectives: To determine whether there is a relation between statin utilisation and coronary heart disease (CHD) mortality in populations with different levels of coronary risk, and whether the relation changes over time.

Design: Ecological study using national databases of dispensed medicines and mortality rates.

Setting: Western European countries with similar public health systems.

Main outcome measures: Population CHD mortality rates (rate/100 000) as a proxy for population coronary risk level, and statin utilisation expressed as Defined Daily Dose per one Thousand Inhabitants per Day (DDD/TID), in each country, for each year between 2000 and 2012. Spearman’s correlation coefficients between CHD mortality and statin utilisation were calculated. Linear regression analysis was used to assess the relation between changes in CHD mortality and statin utilisation over the years.

Results: 12 countries were included in the study. There was a wide range of CHD mortality reduction between the years 2000 and 2012 (from 25.9% in Italy to 57.9% in Denmark) and statin utilisation increase (from 121% in Belgium to 1263% in Denmark). No statistically significant relations were found between CHD mortality rates and statin utilisation, nor between changes in CHD and changes in statin utilisation in the countries over the years 2000 and 2012.

Conclusions: Among the Western European countries studied, the large increase in statin utilisation between 2000 and 2012 was not associated with CHD mortality, nor with its rate of change over the years. Factors different from the individual coronary risk, such as population ageing, health authority programmes, guidelines, media attention and pharmaceutical industry marketing, may have influenced the large increase in statin utilisation. These need to be re-examined with a greater emphasis on prevention strategies.

INTRODUCTION

A substantial decrease in coronary heart disease (CHD) mortality has been observed in Western European countries during the past four decades,1,2 to a great extent attributable to reductions in major risk factors in the populations, mainly dyslipidaemia and hypertension.3–5

Statins reducing cholesterol synthesis were first used in the 1990s. Several clinical trials in both primary and secondary prevention have shown that statins reduce coronary events and mortality.6,7 Since their introduction, the utilisation of statins has increased rapidly in all Western European countries, although the level of utilisation varies widely.8–10 Current guidelines on CHD prevention propose that the decision to start statin treatment in primary prevention should be based on the assessment of the global risk of developing CHD in individual patients.11,12 According to the guidelines, the treatment of high-risk individuals should be prioritised. This has resulted in multiple strategies among Western European...
countries to enhance the prescribing of statins in high-risk individuals, including producing and disseminating guidelines, quality indicators—such as targets for lipid levels—and financial incentives. A reasonable consequence, at the population level, could be that more people are treated in high-risk countries, leading to a higher utilisation of statins in these countries than in countries with low risk. At the same time, of course, statin utilisation should lower the risk by time, which makes prediction more complicated.

It has previously been reported that doctors tend to underestimate coronary risk in high-risk patients, and that statins are overused in individuals with low cardiovascular risk, whereas they are underused in those at high risk. This may result in under-treatment of high-risk patients whereas low-risk individuals may be unnecessarily treated, potentially leading to adverse effects and increased expenditure. Despite the debate about the appropriateness of current prescribing patterns and the effectiveness of strategies to target statin treatment based on CHD risk, whether there is an association between coronary risk in the general population and statin utilisation, and whether this persists over the years, has not been investigated.

In the present study, we analysed the relation between the changes over time in CHD mortality and statin utilisation in a number of Western European countries with a wide spectrum of the level of population coronary risk. Our research questions were (1) whether there would be an association between statin utilisation and CHD mortality when different countries are compared at a certain point in time, and (2) whether the level of change in statin utilisation over the years would be associated with the level of decrease in CHD mortality. The analysis of these relationships may improve our understanding of the appropriateness of statin utilisation.

METHODS
This was an ecological study comparing statin utilisation and CHD mortality between 2000 and 2012, among Western European countries. The countries were chosen to reflect differences in population coronary risk and according to the availability of both, mortality and statin utilisation data. All these countries have similar public health systems, or statutory health insurance with universal coverage, based on direct taxation or income-related contribution.

CHD mortality was used as a proxy measure of population CHD risk level, since it has less diagnostic variance than measurement of individual risk factors. There is evidence that countries with higher levels of risk factors have higher CHD mortality, and a close association has previously been demonstrated between changes in risk factor levels and changes in CHD mortality. Data with ICD-10 codes I20-I25 (ischaemic heart disease), including angina, acute myocardial infarction, subsequent myocardial infarction, complications following acute myocardial infarction and chronic ischaemic heart disease) were extracted from the Organisation for Economic Co-operation and Development (OECD) database. All ages were included. To take into account the possible bias of different age classes in the different countries, we used age-standardised mortality data calculated by the OECD Secretariat, using the total OECD population for 2010 as the reference population, expressed as rates/100 000 population.

Utilisation of statins was assessed using publicly available databases on prescription sales in the countries. The population coverage of each database was 100% (95% for the Netherlands). Since they represent more than 90% of lipid-lowering drugs used in all the countries studied, only statin utilisation was analysed. To make international comparisons in different periods, the Anatomical Therapeutic Chemical (ATC) classification and the standard international method for estimating drug use across populations—the Defined Daily Dose (DDD) per one Thousand Inhabitants per Day (DDD/TID)—were used. The ATC code C10AA and the 2013 DDDs update were used.

Statistical analysis was carried out using Stata V.13 (Stata Corporation, Texas, USA). Volumes of statin utilisation (DDD/TID) were plotted against CHD mortality rates in each country between the years 2000 and 2012. The panel of data was constructed using the reshape command in Stata, so that the values for each country were in different columns, one row for each year. Since each country was represented 13 times, the cluster command in Stata was used to adjust for repeated measures. Spearman’s correlation coefficients between CHD mortality and statin utilisation for each year between 2000 and 2012 were calculated. The relationship between changes in CHD mortality and statins over the years was studied with linear regression, using CHD mortality as a response and statin utilisation and years as independent variables.

RESULTS
There was data available from 12 countries: Finland, Scotland, Germany, Sweden, Norway, Denmark, the Netherlands, Italy, Belgium, Spain, Portugal and France. Data from other Western European countries were not available or limited to a few years (Ireland, Austria), or the data used a drug codification system that was not directly comparable to ATC (England and Wales). CHD mortality rates and statin utilisation in the years 2000 and 2012 are shown in figure 1. A wide range of CHD mortality reduction (from 25.9% in Italy to 57.9% in Denmark) and statin utilisation increase (from 121% in Belgium to 1263% in Denmark) was observed between 2000 and 2012 (table 1). There was no statistically significant correlation between statin utilisation and CHD mortality in any of the years between 2000 and 2012. No significant relation was found between changes in statin utilisation between 2000 and 2012 on the one hand, and
the changes in CHD mortality over the same period on the other hand ($\beta$ coefficient 0.35, 95% CI −0.61 to 1.33).

Coronary mortality in 2012 was highly correlated to CHD in 2000 (p=0.002), whereas no significant correlation was found between statins in 2000 and 2012.

The mean annual change in CHD mortality was plotted against the mean annual change in statin utilisation (figure 2). The mean annual change in statin utilisation varied widely across all countries and was unrelated to the annual change in CHD mortality. Countries with similar decreases in CHD mortality rates (France, Italy, Spain and Portugal) had very different increases in statin utilisation. Conversely, similar increases in statin utilisation were observed in countries with very different reductions in CHD mortality rates. Scotland showed the largest rates of CHD mortality reduction and statin utilisation increase. Taken together, the countries showed a wide range of statin increase, with no apparent relation to the reduction in CHD mortality.

**DISCUSSION**

We found a decrease in CHD mortality and an increase in statin utilisation in all the Western European countries studied. If we accept CHD mortality as a marker of population cardiovascular risk, the relation between statins and CHD mortality may be considered from two angles: as an effect of statins on cardiovascular risk, or as

---

**Table 1** Standardised CHD mortality rates/100 000 and statin utilisation as DDD/TID

| Year | CHD mortality | Statin utilisation | CHD mean annual change (95% CI) | Statins mean annual change (95% CI) |
|------|---------------|-------------------|---------------------------------|-------------------------------------|
|      | 2000          | 2012              | 2000                            | 2012                                |
| Finland | 264.6          | 166               | 17                             | 94.9                                | −7.9 (−8.6 to −7.2) | 7.2 (6.5 to 8.0) |
| Scotland | 239.9          | 123.8             | 17.2                           | 142.8                               | −10.2 (−10.9 to −9.6) | 14.1 (12.7 to 15.4) |
| Germany | 190.8          | 113.4             | 21.4                           | 70.5                                | −7.1 (−7.8 to −6.4) | 4.5 (4.0 to 4.9) |
| Sweden  | 186.6          | 112.7             | 21.8                           | 76.3                                | −6.5 (−6.9 to −6.1) | 5.3 (4.9 to 5.6) |
| Norway  | 173.2          | 87.2              | 30.9                           | 114.6                               | −7.5 (−8.5 to −6.5) | 7.6 (7.1 to 8.1) |
| Denmark | 168            | 70.6              | 8.6                            | 117.3                               | −8.5 (−9.4 to −7.7) | 10.3 (9.4 to 11.2) |
| The Netherlands | 122.5  | 53.6              | 35.6                           | 99.9                                | −6.0 (−6.5 to −5.4) | 6.3 (5.8 to 6.8) |
| Italy   | 113.5          | 84.1              | 6.4                            | 64.5                                | −2.7 (−3.4 to −2.0) | 4.8 (4.6 to 5.0) |
| Belgium | 121.3          | 62.6              | 50.9                           | 112.7                               | −5.1 (−5.6 to −4.7) | 8.5 (7.8 to 9.3) |
| Spain   | 94             | 59.5              | 14.7                           | 91.6                                | −3.0 (−3.3 to −2.8) | 6.6 (6.0 to 7.2) |
| Portugal | 88.6           | 51.7              | 11.1                           | 98.9                                | −3.4 (−4.0 to −2.9) | 8.5 (7.9 to 9.2) |
| France  | 72.8           | 42.6              | 32.3                           | 66.0                                | −2.9 (−3.1 to −2.7) | 3.5 (2.9 to 4.1) |
| Mean    | 153 (60)       | 85 (36)           | 22 (13)                        | 95 (23)                              | −5.9 (−7.4 to −4.3) | 7.2 (5.4 to 9.1) |

Data as in figure 1.
Summary data are expressed as mean (SD) or (95% CI).
DDD/TID, Defined Daily Dose per one Thousand Inhabitants per Day.
changes in statin utilisation following changes in risk levels. However, when the different countries were compared, there was no evidence that higher statin utilisation was associated with lower CHD mortality, nor was there evidence that a high increase in statin utilisation between 2000 and 2012 was related to a larger reduction in CHD mortality.

The overall reduced CHD mortality might be considered as an effect of the increased utilisation of statins. Although several clinical studies have demonstrated that statins reduce the cardiovascular mortality in primary and secondary prevention, the decrease in CHD mortality rates in Western countries started well before statin therapy became available, due to improvement of risk factors, as a result of population-based interventions. Moreover, clinical trials in primary and secondary prevention show that statins lower the absolute risk of coronary death by less than 1–3.5%, which represents a small proportion of the observed reduction. Consequently, it is difficult to demonstrate any population impact of statin utilisation on CHD mortality. This was confirmed in a Swedish study including a large sample of municipalities, where no correlation was shown between statin utilisation and acute myocardial infarction incidence or mortality.

We recently observed that statin utilisation is higher in Stockholm, Sweden, which is a relatively high-risk area, compared to Sicily, Italy, with a lower population risk level. However, the analysis of the time trend of changes in statin utilisation and CHD mortality rates in these regions between 2000 and 2011 showed that statin utilisation increased more rapidly in Sicily, where the reduction in CHD mortality was slower, whereas a smaller increase occurred in Stockholm, with a larger reduction in CHD mortality. Such discordance between time trends may indicate that the doctors’ attitude to initiating statin treatment is influenced by factors not directly related to the actual patient risk, such as the doctors’ gender and length of clinical experience, patients’ attitudes to medicines, drug reimbursement policies, prescribing restrictions and marketing by pharmaceutical companies.

Interpreting the relation between statin utilisation and CHD mortality cannot be limited to the direct relation between drug therapy and clinical outcome. Pharmaceutical expenditure has increased in all European countries during the past decade due to the ageing population, new and expensive medicines, the growing prevalence of chronic diseases, rising patient expectations and greater treatment intensity due to the reduction of the threshold to prevent cardiovascular disease. In the case of statins, health authorities in many countries have introduced measures to increase the prescribing of low-cost generic versus patented statins to reduce expenditure without compromising care. Educational interventions and disease management programmes have also been initiated by health authorities to promote the use of statins in high-risk groups, especially where there is perceived undertreatment. This includes patients with diabetes and a history of stroke. The policy reforms conducted in the different countries have resulted in economical savings while also stimulating an increased prescribing of statins.

Strengths and limitations
The populations we studied represent the real world; therefore they were different from patients included in clinical trials, who are highly selected. There was a wide range of CHD mortality rates among countries, which allowed analysis of changes in statin utilisation in countries with different levels of coronary risk.

There are some limitations to our study. We assumed that CHD mortality represented the population coronary
risk. However, about half of the changes in CHD mortality can be explained by changes in risk factors, whereas the other half are due to treatment or to unknown factors. Differences in the relative proportion of changes in risk factors among countries may have influenced the utilisation of statins. This study has limited statistical power due to small sample size. Ours is an ecological study, but we did not have access to information on individual patient link between CHD risk and statin utilisation. Therefore, our results at country level may not be applicable to single patients (ecological fallacy). A critical issue regarding the effectiveness of statin therapy is the persistence of treatment. Poor adherence to treatment is associated with an increased risk of cardiovascular disease and mortality. Adherence to lipid-lowering treatment shows wide variation, ranging from 37% to 80%, with lower rates in women, young patients, those with low income, patients taking statins for primary prevention and when a statin is prescribed for secondary prevention by a primary care physician, rather than by a cardiologist or neurologist. Differences in the discontinuation rate of statins among countries might have a role in the relation between statin utilisation and CHD mortality. However, we could not assess this in our study as we did not have access to specific patient data, but only to aggregated statin utilisation data.

We also do not know the influence of extensive marketing campaigns by the pharmaceutical industries on doctors' decision about statin treatment in each country. This may be an important factor in treatment decisions, especially targeting low-risk individuals. Also, the media debate about the benefit of giving statins to all those over 50 years, independently from risk scoring, versus the concern about adverse effects, especially myopathy and increased risk of diabetes, may have had different impacts both on doctors and patients in different countries. The extent of statin utilisation for either primary or secondary prevention in each country was not investigated. Cross-sectional studies in European countries have shown large variations in the attainment of treatment targets, in primary and secondary prevention. Doctors' willingness to prescribe statins in primary prevention may also change over time, due to reimbursement changes or guidelines restrictions. Higher prescription rates have been reported in women and the elderly. There is also a socioeconomic gradient in the utilisation of statins. More patients with higher income and educational levels start statin treatment compared to patients with lower income, especially in secondary prevention. The differences among countries might have affected the pattern for prescribing statins.

Clinical implications
Among the Western European countries studied, CHD mortality decreased by approximately 40% whereas statin utilisation increased more than threefold between 2000 and 2012. However, this large growth in statin utilisation over the years did not appear to be related to the coronary risk in the population or to the changes over the years. Factors other than coronary risk, such as demographic changes, socioeconomic factors, healthcare policies—including educational programmes—and pharmaceutical industry marketing, should be taken into account to explain the rapid increase in statin utilisation among Western European countries. On the other hand, although statins have proved effective in the appropriate clinical setting, whether they are appropriately prescribed to those who benefit most, that is, high-risk individuals and whether statins are effective and safe in otherwise healthy people, are matters for debate. Since CHD is largely dependent on health factors, such as diet and exercise, the apparent lack of association we observed between CHD mortality and statin utilisation supports the need for greater implementation of population life-style changes instead of additional initiatives to further enhance statin utilisation to reduce the burden of CHD.

Author affiliations
1Department of Internal Medicine, Ospedale S Elia, Caltanissetta, Italy
2Department of Neurobiology, Care Sciences and Society, Division of Family Medicine, Karolinska Institutet, Stockholm, Sweden
3Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden
4Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
5Centre for Pharmacoepidemiology & Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden
6Public Healthcare Services Committee, Stockholm County Council, Stockholm, Sweden

Acknowledgements The authors thank Carsten Telschow, AOK Research Institute, Berlin, Iain Bishop, NHS National Services, Scotland, Maria Juhasz and Desirée Loikas, Stockholm County Council, Sweden, for providing statin data from Germany, Scotland and Sweden, respectively and Julie Ramsey, National Records of Scotland, for calculating standardised Scottish CHD mortality rates.

Contributors FV was responsible for the design, implementation, analysis and reporting of the study. LB, L-ES, BG and BW provided substantial contributions to the design, analysis and interpretation of data, and all critically revised the manuscript and approved the final version.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
1. Kesteloot H, Sans S, Kromhout D. Dynamics of cardiovascular and all-cause mortality in Western and Eastern Europe between 1970 and 2000. Eur Heart J 2006;27:107–13.

Vancheri F, et al. BMJ Open 2016;6:e010500. doi:10.1136/bmjopen-2015-010500
50. Cederberg H, Stančáková A, Yaluri N, et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015;58:1109–17.
51. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QRResearch database. BMJ 2010;340:c2197.
52. Banegas JR, López-Garcia E, Dalongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011;32:2143–52.
53. Kotseva K, Wood D, Backer GD, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur Heart J 2011;32:2143–52.
54. Pettersson B, Hoffmann M, Wändell P, et al. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy 2012;104:84–91.
55. Damiani G, Federico B, Bianchi C, et al. The impact of regional co-payment and national reimbursement criteria on statins use in Italy: an interrupted time-series analysis. BMC Health Serv Res 2014;14:6.
56. Martikainen JEL, Saastamoinen LKP, Korhonen MJP, et al. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care 2010;48:761–6.